Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sophie Piperno-Neumann

Showing results (41-50 of 148) with videos related to

Pageof 15
Sort By:
European Journal of Cancer (Oxford, England : 1990)|July 18, 2025
Real-life data on tebentafusp in metastatic uveal melanoma patients from four EURACAN Expert CentresMonique K van der Kooij, Ellen Kapiteijn, Piotr Rutkowski, et al.
Bulletin Du Cancer|March 18, 2025
[Radiotherapy in Ewing sarcomas]Line Claude, Sylvie Helfre, Nadège Corradini, et al.
Diagnostic and Interventional Imaging|March 3, 2026
Total tumor volume and growth rate at 3 months on MRI outperform baseline imaging and circulating tumor DNA for predicting survival of patients with metastatic uveal melanoma receiving tebentafuspToulsie Ramtohul, Xavier-Louis Jasawant, José Luis Sandoval, et al.
JAMA Oncology|June 30, 2017
Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical TrialMaud Toulmonde, Nicolas Penel, Julien Adam, et al.
The Journal of Investigative Dermatology|July 17, 2024
Tebentafusp Induces a T-Cell-Driven Rash in Melanocyte-Bearing Skin as an Adverse Event Consistent with the Mechanism of ActionJessica C Hassel, Sarah Stanhope, Alexander Greenshields-Watson, et al.
Cancers|June 16, 2019
Uveal Melanoma: A European Network to Face the Many Challenges of a Rare CancerSophie Piperno-Neumann, Jose Maria Piulats, Matthias Goebeler, et al.
Anticancer Research|March 19, 2017
First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational StudyVeronique Dieras, Simona Pop, Frederique Berger, et al.
Melanoma Management|January 27, 2025
Early palliative care in metastatic uveal melanoma (early together): protocol of a prospective randomized Phase III trialSophie Piperno-Neumann, Leanne de Koning, Timothée Marchal, et al.
European Journal of Cancer (Oxford, England : 1990)|February 12, 2014
Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomasJean-Yves Blay, Michael G Leahy, Binh Bui Nguyen, et al.
Investigative Ophthalmology & Visual Science|January 20, 2009
Genomic profiling and identification of high-risk uveal melanoma by array CGH analysis of primary tumors and liver metastasesJulien Trolet, Philippe Hupé, Isabelle Huon, et al.
Pageof 15

Showing results (41-50 of 148) with videos related to

Sort By:
Pageof 15
European Journal of Cancer (Oxford, England : 1990)|July 18, 2025
Real-life data on tebentafusp in metastatic uveal melanoma patients from four EURACAN Expert CentresMonique K van der Kooij, Ellen Kapiteijn, Piotr Rutkowski, et al.
Bulletin Du Cancer|March 18, 2025
[Radiotherapy in Ewing sarcomas]Line Claude, Sylvie Helfre, Nadège Corradini, et al.
Diagnostic and Interventional Imaging|March 3, 2026
Total tumor volume and growth rate at 3 months on MRI outperform baseline imaging and circulating tumor DNA for predicting survival of patients with metastatic uveal melanoma receiving tebentafuspToulsie Ramtohul, Xavier-Louis Jasawant, José Luis Sandoval, et al.
JAMA Oncology|June 30, 2017
Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical TrialMaud Toulmonde, Nicolas Penel, Julien Adam, et al.
The Journal of Investigative Dermatology|July 17, 2024
Tebentafusp Induces a T-Cell-Driven Rash in Melanocyte-Bearing Skin as an Adverse Event Consistent with the Mechanism of ActionJessica C Hassel, Sarah Stanhope, Alexander Greenshields-Watson, et al.
Cancers|June 16, 2019
Uveal Melanoma: A European Network to Face the Many Challenges of a Rare CancerSophie Piperno-Neumann, Jose Maria Piulats, Matthias Goebeler, et al.
Anticancer Research|March 19, 2017
First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational StudyVeronique Dieras, Simona Pop, Frederique Berger, et al.
Melanoma Management|January 27, 2025
Early palliative care in metastatic uveal melanoma (early together): protocol of a prospective randomized Phase III trialSophie Piperno-Neumann, Leanne de Koning, Timothée Marchal, et al.
European Journal of Cancer (Oxford, England : 1990)|February 12, 2014
Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomasJean-Yves Blay, Michael G Leahy, Binh Bui Nguyen, et al.
Investigative Ophthalmology & Visual Science|January 20, 2009
Genomic profiling and identification of high-risk uveal melanoma by array CGH analysis of primary tumors and liver metastasesJulien Trolet, Philippe Hupé, Isabelle Huon, et al.
Pageof 15